Shipra Gandhi
@gandhi_shipraBreast oncologist, translational researcher @RoswellPark Tweets are my own and not medical advice.
Similar User
@royaryam
@RoswellHemOnc
@JHillengass
@SidYadavMD
@AkritiGJain
@LeiDeng3
@MarkFaberDO
@PallawiTorkaMD
@FilipaLynce
@DipeshUpretyMD
@YaleBreast
@CloneTracker
@KalinskyKevin
@DrDawnHershman
@DrWGradishar
Spotlight Poster Discussion #1 "Racial Outcomes and Disparities" PD1-07 showing Black stage I-III breast cancer patients have worse outcomes, especially if did not attain pCR. Personalized treatment options to improve pCR desperately needed !!! @royaryam #SABCS22 @RoswellPark
We’re excited to invite you to #IMG Community of Practice Town Hall! Join us to discuss ongoing initiatives, future plans, and how to get involved🌟 #IMGOncCop 📅 October 15th 🕒 6:30–7:30 PM EST 🔗 Link: tinyurl.com/2s3jyjee #MedEd #Medtwitter #OncTwitter @ASCO @ASCOTECAG
Excited to share our study on the effectiveness & toxicity of #SG in #mTNBC. T-DXd could be a viable option after SG, for those who had clinical benefit w SG! Thanks to my co-first author Dr. Alaklabi, @gandhi_shipra & co-authors @YAbdouMD @LubnaChaudhary1 @SabaShaikhMD
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative #BreastCancer: brnw.ch/21wNq9w #bcsm @royaryam @gandhi_shipra
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative #BreastCancer: brnw.ch/21wNq9w #bcsm @royaryam @gandhi_shipra
Christmas Morning for this breast oncologist when @DrHBurstein breaks down new data for @DFCI_BreastOnc staff.
The 4th Annual Maria Skłodowska Curie Symposium on Cancer Research and Care @RoswellPark is underway! Looking forward to a great conference, meeting new people, and building new collaborations to advance cancer research! @DrPawelKalinski
Physician-Scientist to Research-Engaged Physician jamanetwork.com/journals/jaman… Happy to share our editorial on physician-scientists & physicians engaged in research. @AAMCtoday
The unmissable Schlam Pocket Algorithms are back! Terrific resource 👇
Updated (non-exhaustive) breast cancer treatment algorithms, now including adjuvant ribociclib and other recent updates. I am happy to be running out of space as treatment options continue to expand! @OncoAlert #bcsm
Well isn't this a gift 🎁 for a Tuesday! #bcsm, welcome our 2nd CDK4/6 approved in the adj setting Remember w/ #ribociclib: 📍3 yrs vs. 2 like abema 📌includes intermediate risk pts including N0 🧷 intermittent vs. continues dosing ⬇️ 💩, ⬆️ neutropenia @OncoAlert
📣 NEW #OncTwitter 🇺🇸 Ribociclib is now FDA-approved for treatment of adults with stage 2 & 3 hormone receptor positive, HER2 negative #breastcancer at high risk of recurrence based on efficacy & safety results of the NATALEE trial. #bcsm #regulatory #ESMO24
#KN522 OS data 5 yrs after the initial pCR presentation 75 months of f/u for chemo +/ pembro I stage II and III #TNBC 🌟 EFS is stable from before with 9% improvement w/ pembro 👏 OS improved by 5% (81.7-> 86.6%) #ESMO24 #ESMOAmbassadors
.@CarmenCriscit brilliantly reviews & contextualizes 2 ph1 studies w/ICI 🔹 ivonescimab in combo w/chemo as 1L tx for TNBC - bispecific Ab 🎯 PD-1 & VEGF 🔹 PM8002/BNT327 in combo w nab-paclitaxel for 1L tx mTNBC - bispecific Ab 🎯 PD-L1 & VEGF-A #ESMO24 @OncoAlert
Agree! Steroids are the mainstay for treating ADC-induced ILD (but cause long-term toxicity) Inhaled steroids are much better tolerated and provide benefit in RT-induced ILD + several other conditions (asthma, COVID) Time to study them for preventing ADC-induced ILD!
We should try this either as primary or secondary prevention for T-Dxd pneumonitis… @PTarantinoMD
Absolute benefit about 5% including node-negative. Important update as this drug moves towards adjuvant approval.
#ESMO24 Natalee 4 yr update with increasing benefit in all subgroups c/w carryover effect. 36% <3 yrs; 20% due to AEs. 8.6% gr 3+ LFTs AEs. Nitrosamine issue 2b imminently resolved. Exciting advance for mod/hi risk ES HR+ BC. @OncoAlert
ABIGAIL randomized phase 2 trial: a taxol induction before ET/abema improved ORR in first line for HR+/HER2- mBC with aggressive features. Long term outcomes are needed to evaluate the potential benefit for this strategy. #ESMO24 #ESMOAmbassadors
We did it! KN522 trial demonstrates an OS benefit with pembrolizumab + NACT in TN eBC It’s encouraging to see what we, as Oncology community, can achieve @myESMO #ESMO24 #ESMOAmbassadors
Genomic analysis of HR+ BRCAm disease More likely to have RB1m, less likely to have TP53 and PIK3CA Enrichment of CD8 T cells, NK cells, macrophage M2 cells, depletion of neutrophils More likely to have high TMB and PDL1 expression @OncoAlert #ESMO24
Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert
A beautifully crafted review “Towards targeting the breast cancer immune microenvironment” in @NatureRevCancer by @LoiSher et al not only closes a gap in our up to date understanding of immune microenvironment, but is graphically 🔝 Bravo. Required read. nature.com/articles/s4156…
Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm
Excellent internal discussion by @antgiorda about use of CDK4/6 after CDK4/6. Personally I consider if long first line CDK4/6 duration, Palbo treated, no visceral crisis, no RB frameshift mutation or PIK3CA/AKT/pTEN.
United States Trends
- 1. Travis Hunter 17,6 B posts
- 2. Clemson 8.349 posts
- 3. Colorado 73,6 B posts
- 4. Arkansas 28,7 B posts
- 5. Zepeda 2.844 posts
- 6. Dabo 1.499 posts
- 7. Quinn 15,1 B posts
- 8. Cam Coleman 1.221 posts
- 9. #SkoBuffs 4.825 posts
- 10. Isaac Wilson N/A
- 11. #HookEm 3.341 posts
- 12. Sean McDonough N/A
- 13. Tulane 3.009 posts
- 14. #iubb N/A
- 15. Northwestern 6.932 posts
- 16. #NWSL N/A
- 17. Sark 2.006 posts
- 18. Pentagon 102 B posts
- 19. Syracuse 34,8 B posts
- 20. Mercer 4.372 posts
Who to follow
-
Arya Roy
@royaryam -
Roswell Park Hematology/Oncology Fellowship
@RoswellHemOnc -
Jens Hillengass
@JHillengass -
Sid Yadav MD, FACP
@SidYadavMD -
Akriti Jain
@AkritiGJain -
Lei Deng, MD (He/Him)
@LeiDeng3 -
Mark Faber
@MarkFaberDO -
Pallawi Torka
@PallawiTorkaMD -
Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸
@FilipaLynce -
Dipesh Uprety MD FACP
@DipeshUpretyMD -
YaleBreastCancer
@YaleBreast -
Abhay Singh
@CloneTracker -
Kevin Kalinsky, MD, MS, FASCO
@KalinskyKevin -
Dawn Hershman
@DrDawnHershman -
William Gradishar, MD
@DrWGradishar
Something went wrong.
Something went wrong.